A Review of Computational Approaches Targeting SARS-CoV-2 Main Protease to the Discovery of New Potential Antiviral Compounds

A Review of Computational Approaches Targeting SARS-CoV-2 Main Protease to the Discovery of New Potential Antiviral Compounds

Pippa Scott2026-10-30T13:31:20+00:00

A Review of Computational Approaches Targeting SARS-CoV-2 Main Protease to the Discovery of New

A Review of Computational Approaches Targeting SARS-CoV-2 Main Protease to the Discovery of New Potential Antiviral CompoundsPippa Scott2026-10-30T13:31:20+00:00

The Discovery of GSK3227634: A Potent Inhaled Inhibitor of the KEAP1/NRF2 Protein−Protein Interaction for the Treatment of Chronic Obstructive Pulmonary Disease

The Discovery of GSK3227634: A Potent Inhaled Inhibitor of the KEAP1/NRF2 Protein−Protein Interaction for the Treatment of Chronic Obstructive Pulmonary Disease

Pippa Scott2026-10-30T13:32:07+00:00

The Discovery of GSK3227634: A Potent Inhaled Inhibitor of the KEAP1/NRF2 Protein−Protein Interaction for

The Discovery of GSK3227634: A Potent Inhaled Inhibitor of the KEAP1/NRF2 Protein−Protein Interaction for the Treatment of Chronic Obstructive Pulmonary DiseasePippa Scott2026-10-30T13:32:07+00:00

Rational Design and In-Vivo Validation of Capsid Inhibitors for Enterovirus D68

Rational Design and In-Vivo Validation of Capsid Inhibitors for Enterovirus D68

Pippa Scott2026-10-16T11:19:20+00:00

Rational Design and In-Vivo Validation of Capsid Inhibitors for Enterovirus D68 The viral capsid

Rational Design and In-Vivo Validation of Capsid Inhibitors for Enterovirus D68Pippa Scott2026-10-16T11:19:20+00:00

Development of a random background to understand ligand optimization

Development of a random background to understand ligand optimization

Pippa Scott2026-10-16T11:24:13+00:00

Development of a random background to understand ligand optimization As a working medicinal

Development of a random background to understand ligand optimizationPippa Scott2026-10-16T11:24:13+00:00

Discovery of SMD-6346: A Potent, Selective, and Orally Active SMARCA2 Degrader for Targeting SMARCA4-Deficient Human Cancer

Discovery of SMD-6346: A Potent, Selective, and Orally Active SMARCA2 Degrader for Targeting SMARCA4-Deficient Human Cancer

Pippa Scott2026-08-27T16:25:49+00:00

Discovery of SMD-6346: A Potent, Selective, and Orally Active SMARCA2 Degrader for Targeting

Discovery of SMD-6346: A Potent, Selective, and Orally Active SMARCA2 Degrader for Targeting SMARCA4-Deficient Human CancerPippa Scott2026-08-27T16:25:49+00:00

Cell Permeability and Solubility of Series of Macrocycles and Linear Matched Pairs – July 2026

Cell Permeability and Solubility of Series of Macrocycles and Linear Matched Pairs – July 2026

Pippa Scott2026-08-24T16:33:08+00:00

What is in a structure? Cell Permeability and Solubility of Series of Macrocycles and

Cell Permeability and Solubility of Series of Macrocycles and Linear Matched Pairs – July 2026Pippa Scott2026-08-24T16:33:08+00:00

Overrepresentation Bias in Blood−Brain Barrier Permeability Prediction Models- July 2026

Overrepresentation Bias in Blood−Brain Barrier Permeability Prediction Models- July 2026

Pippa Scott2026-08-24T16:34:38+00:00

My eye was drawn directly to the title of this paper and I

Overrepresentation Bias in Blood−Brain Barrier Permeability Prediction Models- July 2026Pippa Scott2026-08-24T16:34:38+00:00

Spiro-Azetidine Oxindoles as Long-Acting Injectable RSV Antivirals- June 2026

Spiro-Azetidine Oxindoles as Long-Acting Injectable RSV Antivirals- June 2026

MedChemica2026-08-11T12:55:10+00:00

Spiro-Azetidine Oxindoles as Long-Acting Injectables for Pre-Exposure Prophylaxis against Respiratory Syncytial Virus Infections J.

Spiro-Azetidine Oxindoles as Long-Acting Injectable RSV Antivirals- June 2026MedChemica2026-08-11T12:55:10+00:00

Binding Free Energy Calculations for Drug Discovery- June 2026

Binding Free Energy Calculations for Drug Discovery- June 2026

Pippa Scott2026-08-11T12:55:11+00:00

Large-Scale Collaborative Assessment of Binding Free Energy Calculations for Drug Discovery Using OpenFE J.

Binding Free Energy Calculations for Drug Discovery- June 2026Pippa Scott2026-08-11T12:55:11+00:00

An Automated Workflow for Diagnosing Sampling Issues Caused by Slow Torsional Motions in Molecular Simulations- May 2026

An Automated Workflow for Diagnosing Sampling Issues Caused by Slow Torsional Motions in Molecular Simulations- May 2026

Pippa Scott2026-08-11T12:55:11+00:00

An Automated Workflow for Diagnosing Sampling Issues Caused by Slow Torsional Motions in Molecular

An Automated Workflow for Diagnosing Sampling Issues Caused by Slow Torsional Motions in Molecular Simulations- May 2026Pippa Scott2026-08-11T12:55:11+00:00

MCPairs

Overview

Pricing and Plans

Modules

RuleDesign®

CoreDesign®

SpotDesign®

SARkush®

MyPairs

pMMPA

Toxophores

Pharmacophores

Compound to Pairs

Cheminformatics Tools

A Review of Computational Approaches Targeting SARS-CoV-2 Main Protease to the Discovery of New Potential Antiviral Compounds

The Discovery of GSK3227634: A Potent Inhaled Inhibitor of the KEAP1/NRF2 Protein−Protein Interaction for the Treatment of Chronic Obstructive Pulmonary Disease

Rational Design and In-Vivo Validation of Capsid Inhibitors for Enterovirus D68

Development of a random background to understand ligand optimization

Discovery of SMD-6346: A Potent, Selective, and Orally Active SMARCA2 Degrader for Targeting SMARCA4-Deficient Human Cancer

Cell Permeability and Solubility of Series of Macrocycles and Linear Matched Pairs – July 2026

Overrepresentation Bias in Blood−Brain Barrier Permeability Prediction Models- July 2026

Spiro-Azetidine Oxindoles as Long-Acting Injectable RSV Antivirals- June 2026

Binding Free Energy Calculations for Drug Discovery- June 2026

An Automated Workflow for Diagnosing Sampling Issues Caused by Slow Torsional Motions in Molecular Simulations- May 2026

Navigation

Company info

connect

subscribe to our newsletter

Let’s Make Things Happen

Contact Info